Dr. Wagner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2005- Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1997
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1999 - 2026- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors Start of enrollment: 2007 Aug 01
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
- Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia Start of enrollment: 2014 Dec 01
Publications & Presentations
PubMed
- Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.Jiangang Liu, David S Moura, Robin L Jones, Amit Aggarwal, Ebert J Philip, Jennifer Wright, Javier Martín-Broto, Andrew J Wagner, William D Tap> ;Clinical Cancer Research. 2024 Mar 27
- Phase II Trial ofSirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update.Ganjoo, K., Van Tine, B., Chugh, R., Hornick, J., Du, H., Ding, L., Schmid, A., Navarro, W., Kwiatkowski, D., Wagner, A., Ravi, V., Riedel, R., Cranmer, L., Gordon, E....> ;Journal of Clinical Oncology. 2024 Mar 1
- Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.Candace L Haddox, Emanuele Mazzola, Jia-Ren Lin, Joanna Baginska, Allison Nau, Jason L Weirather, Adrian Marino-Enriquez, Jeffrey A Morgan, Priscilla Merriam, Andrew J...> ;Clinical Cancer Research. 2024 Apr 1
- Join now to see all
Lectures
- ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open l...2019 ASCO Annual Meeting - 6/1/2019
- Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su)...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
A Rare Occurrence of BHD and PEComa – Perspectives from a Patient and a DoctorMarch 18th, 2022
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComaJune 4th, 2019- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
South Shore HospitalSouth Weymouth, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's Faulkner HospitalJamaica Plain, Massachusetts
Salem HospitalSalem, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
